Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD

Active, not recruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Pulmonary Fibrosis
Interventions
DIAGNOSTIC_TEST

Electronic nose

First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow \<0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.

Trial Locations (5)

69126

Thoraxklinik Heidelberg, Heidelberg

NSW 2050

Royal Prince Alfred Hospital, Camperdown

Unknown

University Lyon 1, Louis Pradel hospital, Lyon. FranceService de pneumologie, hôpital Louis Pradel, Lyon

3000 CA

Erasmus MC, Rotterdam

SW3 6NP

Royal Brompton Hospital, London

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER